Investigating body composition and its effects on kidney cancer outcomes
Body composition and the obesity paradox in clear cell renal cell carcinoma
This study is looking at how different aspects of body composition, not just weight, can impact survival for people with clear cell kidney cancer, using CT scans and tumor samples to find helpful insights for better health recommendations.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10675702 on NIH RePORTER |
What this research studies
This research focuses on clear cell renal cell carcinoma (ccRCC), a serious type of kidney cancer, and aims to understand how body composition, beyond just body mass index (BMI), affects patient prognosis. By analyzing pre-surgical CT scans and tumor samples from a large group of ccRCC patients, the study seeks to identify specific body composition features that may influence survival rates. The goal is to provide insights that could lead to better weight management recommendations and prognostic factors for patients with this cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with non-metastatic clear cell renal cell carcinoma who have undergone nephrectomy.
Not a fit: Patients with metastatic clear cell renal cell carcinoma or those who have not undergone nephrectomy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies and personalized care for kidney cancer patients based on their body composition.
How similar studies have performed: Previous research has indicated that body composition can significantly impact cancer outcomes, suggesting that this approach may yield valuable insights.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Furberg-Barnes, Anna Helena — Sloan-Kettering Inst Can Research
- Study coordinator: Furberg-Barnes, Anna Helena
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.